Kite Pharma, Inc.
Sep 3, 2015

Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine

SANTA MONICA, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today commended members of its Scientific Advisory Board (SAB) for the honors and recognition they have received recently for their unique contributions to medicine:

"We are thrilled to acknowledge Owen's reappointment to the President's Cancer Panel, as well as Zelig's receipt of the Israel Prize, and James' election to the Institute of Medicine," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite.  "Owen's research has greatly advanced the understanding of human leukemias and immune disorders, propelling the development of approved targeted cancer therapies, including imatinib (Gleevec®). Zelig's research led to the design of leading chimeric antigen receptor (CAR) constructs and the establishment of promising therapeutic strategies that paved the way for clinical trials of CAR approaches at leading centers. Further, as founder and director of the UCLA Human Gene Medicine Program, James built one of the largest and well-respected gene therapy programs in the world." Dr. Belldegrun added, "Our team is honored to work alongside these acclaimed researchers, and we look forward to their continuing contributions to medicine."

About Kite Pharma, Inc.

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.

CONTACT: Kite Pharma

         Cynthia M. Butitta

         Chief Financial Officer and Chief Operating Officer

         310-824-9999

         

         For Media: Justin Jackson

         For Investor Inquiries: Lisa Burns

         Burns McClellan

         212-213-0006

         jjackson@burnsmc.com

         lburns@burnsmc.com